相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A High-Affinity Inhibitor of Human CD59 Enhances Complement-Mediated Virolysis of HIV-1: Implications for Treatment of HIV-1/AIDS
Weiguo Hu et al.
JOURNAL OF IMMUNOLOGY (2010)
CD59 Silencing via Retrovirus-Mediated RNA Interference Enhanced Complement-Mediated Cell Damage in Ovary Cancer
Xuexiang Shi et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2009)
In vivo Model of Follicular Lymphoma Resistant to Rituximab
Stephane Dalle et al.
CLINICAL CANCER RESEARCH (2009)
Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders
Jorge Castillo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Intermedilysin-Receptor Interactions during Assembly of the Pore Complex ASSEMBLY INTERMEDIATES INCREASE HOST CELL SUSCEPTIBILITY TO COMPLEMENT-MEDIATED LYSIS
Stephanie LaChapelle et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Update in the management of chronic lymphocytic leukemia
Kami J. Maddocks et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59
Timothy R. Hughes et al.
MOLECULAR IMMUNOLOGY (2009)
Development of IGF-IR Inhibitors in Pediatric Sarcomas
E. Anders Kolb et al.
CURRENT ONCOLOGY REPORTS (2009)
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
Anton Hagenbeek et al.
BLOOD (2008)
Anti-CD20 monoclonal antibody therapy in multiple myeloma
Prashant Kapoor et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
被撤回的出版物: Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma(Retracted article. See vol. 73, pg. 6839, 2013)
Rossen M. Donev et al.
CANCER RESEARCH (2008)
The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy
Xuhui Zhou et al.
ONCOLOGIST (2008)
Rapid conditional targeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin
Weiguo Hu et al.
NATURE MEDICINE (2008)
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab
Paolo Macor et al.
CANCER RESEARCH (2007)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
Crystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complex
Yuxiang Huang et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2007)
'Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions'
B. Bonavida
ONCOGENE (2007)
Neutralizing human antibodies against CD55 and CD59 targeted to lymphoma cells in vivo potentiate the therapeutic effect of Rituximab
R. Macor et al.
MOLECULAR IMMUNOLOGY (2007)
Defining the CD59-C9 binding interaction
Yuxiang Huang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
K Takei et al.
LEUKEMIA RESEARCH (2006)
Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy
L Bjorge et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2006)
Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy - 15-year experience in 789 patients treated at a single institution
G Bacci et al.
CANCER (2006)
Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins
RK Tweten
INFECTION AND IMMUNITY (2005)
Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59
F Ziller et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Human CD59 is a receptor for the cholesterol-dependent cytolysin intermedilysin
KS Giddings et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2004)
Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors
Z Fishelson et al.
MOLECULAR IMMUNOLOGY (2003)
Mechanism of action and resistance to monoclonal antibody therapy
N Villamor et al.
SEMINARS IN ONCOLOGY (2003)
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
J Golay et al.
BLOOD (2001)
Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies
SP Treon et al.
JOURNAL OF IMMUNOTHERAPY (2001)
分享论文
